Gambaryan S, Häusler C, Markert T, Pöhler D, Jarchau T, Walter U, Haase W, Kurtz A, Lohmann S M
Medizinische Universitäts-Klinik, Klinische Biochemie and Pathobiochemie, Würzburg, Germany.
J Clin Invest. 1996 Aug 1;98(3):662-70. doi: 10.1172/JCI118837.
cGMP-based regulatory systems are vital for counteracting the renin-angiotensin system (RAS) which promotes volume expansion and high blood pressure. Natriuretic peptides and nitric oxide acting through their second messenger cGMP normally increase natriuresis and diuresis, and regulate renin release; however, the severe pathological state of cardiac heart failure is characterized by elevated levels of atrial natriuretic peptide that are no longer able to effectively oppose exaggerated RAS effects. There is presently limited information on the intracellular effectors of cGMP actions in the kidney. Recently we reported the cloning of the cDNA for type II cGMP-dependent protein kinase (cGK II), which is highly enriched in intestinal mucosa but was also detected for the first time in kidney. In the present study, cGK II was localized to juxtaglomerular (JG) cells, the ascending thin limb (ATL), and to a lesser extent the brush border of proximal tubules. An activator of renin gene expression, the angiotensin II type I receptor inhibitor, losartan, increased cGK II mRNA and protein three to fourfold in JG cells. In other experiments, water deprivation increased cGK II mRNA and protein three to fourfold in the inner medulla where both cGK II, and a kidney specific CI- channel shown by others to be regulated by dehydration, are localized in the ATL. Whereas additional data suggest that cGK I may primarily mediate cGMP-related changes in renal hemodynamics, cGK II may regulate renin release and ATL ion transport.
基于环磷酸鸟苷(cGMP)的调节系统对于对抗促进血容量增加和高血压的肾素-血管紧张素系统(RAS)至关重要。利钠肽和一氧化氮通过其第二信使cGMP发挥作用,通常会增加尿钠排泄和利尿,并调节肾素释放;然而,严重的心力衰竭病理状态的特征是心房利钠肽水平升高,但不再能够有效对抗过度的RAS效应。目前关于cGMP在肾脏中作用的细胞内效应器的信息有限。最近我们报道了II型cGMP依赖性蛋白激酶(cGK II)的cDNA克隆,其在肠黏膜中高度富集,但首次在肾脏中也被检测到。在本研究中,cGK II定位于肾小球旁(JG)细胞、髓袢升支细段(ATL),在较小程度上也定位于近端小管的刷状缘。肾素基因表达的激活剂、血管紧张素II 1型受体抑制剂氯沙坦可使JG细胞中的cGK II mRNA和蛋白增加三到四倍。在其他实验中,禁水使髓质内层的cGK II mRNA和蛋白增加三到四倍,cGK II以及其他人发现的一种受脱水调节的肾脏特异性氯离子通道都定位于ATL。虽然其他数据表明cGK I可能主要介导肾脏血流动力学中与cGMP相关的变化,但cGK II可能调节肾素释放和ATL的离子转运。